Stay updated on Sasanlimab in Advanced Malignancies Clinical Trial
Sign up to get notified when there's something new on the Sasanlimab in Advanced Malignancies Clinical Trial page.

Latest updates to the Sasanlimab in Advanced Malignancies Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has undergone significant content removal, particularly details regarding a Phase 1b/2 study protocol for PF-06801591, including inclusion and exclusion criteria for participants with advanced malignancies. Additionally, a new version revision has been noted.SummaryDifference14%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 18, 2025. However, the removal of the date March 25, 2025, does not significantly impact the core content.SummaryDifference0.3%
- Check37 days agoChange DetectedThe page has been updated to reflect the latest version as v2.14.3, with a new last update date of March 25, 2025, replacing the previous version v2.14.2 and its last update date of February 18, 2025.SummaryDifference0.2%
- Check73 days agoChange DetectedThe page has updated the number of study locations from 54 to 42 and added specific locations in Ukraine and Russia, including the Zhytomyr Regional Oncology Dispensary. Additionally, several outdated dates have been removed.SummaryDifference8%
- Check88 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1.0%
Stay in the know with updates to Sasanlimab in Advanced Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sasanlimab in Advanced Malignancies Clinical Trial page.